etranacogene dezaparvovec
First NHS patient treated with CSL Behring’s haemophilia B gene therapy Hemgenix
The genetic bleeding disorder affects more than 2,000 people in the UK
GSK’s Blenrep combination recommended by NICE to treat multiple myeloma
The decision means that eligible patients in England will be the first in the world to access the combination
NICE recommends Gideon Richter’s Ryeqo as first daily pill for endometriosis
Around 1,000 patients could benefit from the relugolix combination therapy every year
Amgen’s Blincyto recommended by NICE for new adult leukaemia indication
Up to 50% of acute lymphoblastic leukaemia patients will relapse after initial treatment
EC approves CSL’s Andembry to prevent hereditary angioedema attacks
Approximately one in every 50,000 people worldwide are affected by the rare genetic disorder
CSL Behring announces four-year results for haemophilia B gene therapy Hemgenix
The genetic bleeding disorder affects an estimated one per every 19,283 male births in the US
MHRA approves CSL’s Andembry to treat angioedema attacks in HAE patients
The rare genetic condition occurs in approximately one in every 50,000 people in the UK
AstraZeneca receives NICE recommendations for lung cancer drugs Tagrisso and Imfinzi
More than 49,000 people are diagnosed with lung cancer in the UK each year
NICE recommends Santhera’s Duchenne muscular dystrophy drug Agamree
Approximately 1,700 patients with the muscle-wasting disorder in England are expected to benefit from the decision
NICE recommends Immunocore’s Kimmtrak as first drug for aggressive eye cancer
More than 100 patients are expected to be eligible for the treatment every year
NICE recommends Blueprint Medicines’ Ayvakyt to treat rare blood disorder
Systemic mastocytosis affects approximately one in every 10,000 people in the UK
Pfizer’s Elrexfio recommended by NICE to treat relapsed and refractory multiple myeloma
Approximately 5,000 people are diagnosed with the disease every year in England